No Data
The dragon and tiger list shows that Hainan Shuangcheng Pharmaceuticals has hit the daily limit, with a net Buy of 91.93 million yuan through HK->SZ.
Hainan Shuangcheng Pharmaceuticals (002693.SZ) has hit the limit up today, with a Turnover Ratio of 23.4% and a trading volume of 0.936 billion yuan. According to the dragon and tiger list data, HK->SZ has bought 0.124 billion yuan, sold 32.5246 million yuan, resulting in a net purchase of 91.93 million yuan; the speculator "Algo" ranked second in the buying list with a net purchase of 29.0199 million yuan. (Gelonghui)
Hainan Shuangcheng Pharmaceuticals (002693.SZ): The company's Stocks Trade may face Delisted risk warnings after the disclosure of the 2024 annual report.
Gelonghui, April 14丨Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that according to the preliminary calculations by the company's financial department, the net income attributable to the shareholders of the listed company for the fiscal year 2024 is expected to be negative, and the revenue after deductions is expected to be below 0.3 billion yuan. According to the relevant provisions of the Shenzhen Stock Exchange's stock listing rules, the company's stocks may be subject to delisting risk warnings (with "*ST" prefixed to the stock abbreviation) after the disclosure of the 2024 annual report. Investors are advised to pay attention to investment risks. The company's "2024 Annual Report" is scheduled to be disclosed on April 29, 2025, in designated information disclosure media.
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Currently, there are no restructuring plans.
On April 1, Gelonghui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) stated on the investor interaction platform that the company currently has no restructuring plans.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) May Have Run Too Fast Too Soon With Recent 36% Price Plummet
Shuangcheng Pharmaceuticals Scraps Plan to Acquire Aura Semiconductor Via Share Issuance
The "king of monsters" in the A-shares has fallen: Hainan Shuangcheng Pharmaceuticals has terminated its restructuring late at night, potentially facing a delisting crisis.
The sky has fallen.
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some Debt
